Metadherin: A Therapeutic Target in Multiple Cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Altered gene and protein expression is critical for cancer development.
• Metadherin (MTDH), also known as Astrocyte Elevated Gene 1 (AEG-1), is increasingly recognized for its role in cancer progression.
• Elevated MTDH expression is observed in various cancers like breast, prostate, liver, and esophageal cancers, but not in normal tissues.

Purpose of the Study:

• To review the multifaceted functions of MTDH in the context of various cancers.
• To highlight MTDH's role as a potential tumor-associated antigen.
• To discuss MTDH's implications as a therapeutic target due to its link with chemoresistance.

Main Methods:

• Literature review of studies investigating MTDH expression and function in cancer.
• Analysis of MTDH's involvement in key signaling pathways (PI3K/Akt, NF-κB, Wnt/β-catenin, MAPK).
• Examination of the relationship between MTDH, microRNAs, and cancer progression.

Main Results:

• MTDH expression is significantly elevated in multiple human cancers compared to non-malignant tissues.
• MTDH regulates critical signaling pathways that enhance tumorigenesis and metastasis.
• Increased MTDH levels correlate with tumor chemoresistance.

Conclusions:

• MTDH plays a significant role in promoting cancer progression, metastasis, and chemoresistance.
• MTDH represents a promising tumor-associated antigen and a potential therapeutic target for various cancers.
• Further research into MTDH's functions can lead to novel cancer treatment strategies.